REMS Assessments Need Very Recent Data, FDA Draft Guidance Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sponsors conducting assessments of a product’s Risk Evaluation and Mitigation Strategy will need to complete them within 60 days of collecting the last piece of data, according to a draft FDA guidance.
You may also be interested in...
Comparative Effectiveness Reaches Into Drug Reviews, FDA Documents Show
As the health care reform debate focuses on the appropriate role of comparative effectiveness research, a look at FDA’s review practices gives some insight into how the agency already takes the concept into account in its review decisions.
Comparative Effectiveness Reaches Into Drug Reviews, FDA Documents Show
As the health care reform debate focuses on the appropriate role of comparative effectiveness research, a look at FDA’s review practices gives some insight into how the agency already takes the concept into account in its review decisions.
REMS Need To Be More Easily Modified, Attorney Says; Prior Approval Supplements Too Cumbersome
FDA could facilitate improvements to Risk Evaluation and Mitigation Strategies by giving companies some discretion to modify REMS elements, according to Hogan and Hartson partner Meredith Manning